Inhibitor Report for: Pyrimidinone-inhibitor1 General
Type Pyrimidine , Piperazine Chemical_Nomenclature 7-[(2-chlorophenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Canonical SMILES CN1C2=C(C(=O)N(C1=O)C)N(C(=N2)N3CCNCC3)CC4=CC=CC=C4Cl InChI InChI=1S/C18H21ClN6O2/c1-22-15-14(16(26)23(2)18(22)27)25(11-12-5-3-4-6-13(12)19)17(21-15)24-9-7-20-8-10-24/h3-6,20H,7-11H2,1-2H3 InChIKey PDZWWGBRZISNRL-UHFFFAOYSA-N PDZWWGBRZISNRL-UHFFFAOYSA-O Other name(s) RUF ; 3g0c ; AC1OKWT8 ; 374612-08-5 ; F3259-0358 ; 7-(2-chlorobenzyl)-1,3-dimethyl-8-(piperazin-1-yl)-1H-purine-2,6(3H,7H)-dione ; 7-[(2-chlorophenyl)methyl]-1,3-dimethyl-8-(piperazin-1-yl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione ; 7-[(2-chlorophenyl)methyl]-1,3-dimethyl-8-piperazinyl-1,3,7-trihydropurine-2,6-dione ; BAS 01547192
________________________________________________________________________________________________
Target
Families | Pyrimidinone-inhibitor1 ligand of proteins in family: DPP4N_Peptidase_S9 Stucture | 1 structure : 3G0C : Crystal structure of Dipeptidyl Peptidase IV in complex with a pyrimidinedione inhibitor 1 Protein | human-DPP4
References:
Title: Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IVZhang Z , Wallace MB , Feng J , Stafford JA , Skene RJ , Shi L , Lee B , Aertgeerts K , Jennings A and Gwaltney SL <5 more author(s)> Zhang Z , Wallace MB , Feng J , Stafford JA , Skene RJ , Shi L , Lee B , Aertgeerts K , Jennings A , Xu R , Kassel DB , Kaldor SW , Navre M , Webb DR , Gwaltney SL (- 5) Ref: Journal of Medicinal Chemistry, 54 :510, 2011 : PubMed Abstract ESTHER: Zhang_2011_J.Med.Chem_54_510 PubMedSearch: Zhang 2011 J.Med.Chem 54 510 PubMedID: 21186796 Gene_locus related to this paper: human-DPP4 Inhibitor(s) related to this paper: Pyrimidinone-inhibitor1 ,
Pyrimidinone-inhibitor3 ,
Xanthine-inhibitor-4 ,
CHEMBL2159182 ,
Alogliptin Abstract
The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.
